Page 1 of 22 UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

OFFICE OF CHEMICAL SAFETY AND
POLLUTION PREVENTION

December 1 5 , 2015

MEMORANDUM

SUBJECT: Ethics Review of Completed Study entitled, “ Field Testing of S

. C

. Johnson Personal Mosquito Repellent Products to Support their Use of the EPA Repellency Awareness Graphic” for MARK

- 5 OFF! Family Care Insect Repellent I V (Unscented)

FROM: Maureen Lydon, Human Research Ethics Review Officer

Office of the Director Office of Pesticide Programs

TO: Marietta Echeverria, Chief, Invertebrate

- Vertebrate Branch 1 Registration Division Office of Pesticide Programs

REF: Edward Laznicka (2015) Field Testing of S

. C

. Johnson Personal Mosquito Repellent Products to Support their Use of the EPA Repellency Awareness Graphic , October 21

, 2015. 150 pages, Test Substance MARK

- 5 OFF! Family Care Insect Repellent I V ( Unscented OFF! Skintastic Spray Insect Repellent, EPA Reg. No. 4822

- 395 ) GLP Study No. 8 67 E1

I have reviewed available information concerning the ethical conduct of the

referenced research study

, “ Field Testing of S

. C

. Johnson Personal Mosquito Repellent Products to Support their Use of the EPA Repellency Awareness Graphic ” for test

s ubstance MARK

- 5 OFF! Family Care Insect Repellent I V ( Unscented OFF! Skintastic Spray Insect Repellent, EPA Reg. No. 4822

- 395). I f the research is determined to be scientifically acceptable, I f ind no barrier in regulation to the U.S. Environmental Protection Agency’s (EPA’s) reliance on this study in actions under the Federal Insecticide, Fungicide, or Rodenticide Act (FIFRA) or the Fede ral Food, Drug, and Cosmetic Act (FFDCA)

. The Human Studies Review Board (HSRB) will be asked to comment on this study.

Completeness of SubmissionPage 2 of 22 A ll requirements of §26.1303 were satisfactorily addressed in the completion of this study as noted in th e checklist in Attachment 1.

Purpose and summary of study

The purpose of this study was to establish the complete protection time (CPT) of

MARK

- 5 OFF! Family Care Insect Repellent I V (Unscented) , which was previously registered and assessed by EPA, in the field against populations of wild mosquitoes, using human subjects. Testing took place at two geographically and ecologically distinct field sites (Wisconsin and Florida). The protocol called for 10 volunteer subjects at each test

site with two un treated control subjects at each site. Table 7 summarizing test subject participation was included in each study; an updated version of this table, supplied by S.C.

Johnson

, is included in Attachment 2. As noted in the updated table 7, 24 human subjects

we re assigned to the tests and 24 completed the testing at the Wisconsin and Florida sites.

Hu man subjects were used because no reliable models or surrogates have been found to adequately predict the duration of efficacy of topically

- applied insect repellents. Since the repellent test products have all been registered by EPA, they have already been found to present little or no risk when used as directed on their labels. The precautions taken to mitigate hazards associated with the study are di scuss ed on pages 17

- 19 (of 150 ) of the completed study and were consistent with the approved protocol.

Testing was completed in Wisconsin on a single day and then in Florida on a single day. The Study Director assembled all test subjects in an area within walk ing distance of the test site for testing preparation (limb preparation, suiting up and test s ubstance application, etc.). Tent enclosure was provided to protect all personnel during this process from mosquitoes present at this location. Each subject was given and instructed to put on a bug suit pants and jacket. This suit is made of tightly woven nylon which allows air exchange but is impenetrable to mosquito bites. The bottoms of the pant legs and ends of the sleeves fit snuggly around the wearer's shoe or wrist respectively; this keeps mosquitoes out. There is also mesh on the sides of the jacket (under arm) for better breathability. The suit has drawstring band around the waist and a mesh area around the face (a zipper allows removal of this mesh around the face). Gloves were provided to protect the hands from mosquito bites. After washing their limbs, subjects put on the bug suit prior to treatment to help reduce any occurrence of abrading or contacting the area of

the skin that will be treated. Each s ubject rolled up the sleeve of their bug suit for their

forearm treatment.

The test substance was applied to human forearms. Starting t hirty minutes after test substance application, there were 5 minute exposures to mosquito e s in the field at 30

minute in tervals until repellent break

- down occurred, or up to the time that the study

director ended the test . Repellency was measured as the time between application of a test
substance and the first confirmed l anding. A “landing” occurred when a mosquito alighte d

on the tre ated test skin of a subject. A “ First Confirmed Landing ” is when two or more land ing s occurred in any five minute exposure period or, when one land ing occurred in

suc h an exposure period and another land ing occurred in the next exposure period.Page 3 of 22 The median duration for Wisconsin and Florida was 2 .0 hours . The duration of the

CPT for the repellency awareness graphic will be based on the EPA Repellency Awareness

Guidance for Skin

- Applied Insect Repellent Products, EPA Document No. 730

- C

- 13

- 001,

wh ich states, "The mosquito claim should be calculated using the most conservative (i.e., lowest) CPT from all available field studies" and "The number of hours of protection appearing on the repellency awareness graphic should be expressed as a whole number . If

the most conservative calculated CPT is not a whole number, EPA recommends rounding

down to the nearest whole number." T he data supports a 2 hour duration for use on the repellency awareness graphic

.

IRB Approval of Revised Final Protocol

The protocol for this study was approved by the overseeing institutional review board, the Schulman Associates I nstitutional Review Board ( SA IRB) , and submitted to

EPA in draft form for r eview . The protocol and EPA’ s review

, dated March 31, 2015

, were dis cussed in a public meeting by the Human Studies Review Boa rd (HSRB) on April

22

- 23 , 201 5

. Per the final HSRB meeting report

, dated June 23 , 2014, the HSRB

con cluded that “the amended protocol , when approved by the SAIRB, should meet all applicable ethical standards for the protection of human subjects of research, and all requirements for documentation of ethical conduct of the research. If this study is determined to be scientifically valid a nd relevant, there is no regulatory barrier to EPA’s

reliance on it in actions under FIFRA or Section 408 of FFDAC.”

In follow

- up to the April 22

- 23 , 201 5 HSRB meeting

, S.C. Johnson revised the protocol

, telephone screening script for initial contact

, script for follow

- up contact, and

consent form to address comments, including the EPA and HSRB comments described in

Attachment 3

, and submitted the revised documents t o the Institutional Review Board (IRB) for review and approval prior to initiating the study

.

The SAIRB approv als relevant to this study and associated approval dates are listed

below.

Chronology of SA IRB Final Approvals after April 2015 HSRB Meeting

a) 7/10 /15

– The SAIRB notified S.C. Johnson that the protocol and informed consent forms were approved by the SAIRB on the dates noted below.

b) 7/9 /15

– The SAIRB a pproved , via expedited r eview, the updated recruitment/ phone script for screening candidates via an initial and follow

- up call

.

c) 7/7 /15

– The SAIRB full board approved the protocol dated 6/26/15 and informed

consent form which took into account EPA and HSRB comments.

The June 26, 2015 protocol , which includes the SA IRB

- approved changes, is in Appendix A to t he completed study

. The consent form approved by the SAIRB is date

stamped 7/10/15 and included in the IRB correspondence file (beginning on page 84 of 398.)Page 4 of 22 The emails and/or forms requesting change s and the IRB ’s review and approval

notifications are provided in the file entitled, “ IRB Correspondence for Completed Research Submissions of Field Testing of S.C. Johnson Personal Mosquito Repellent Products to Support Their Use of the EPA Repellency Awareness Graphic .” The aforementioned SAIRB approval da tes are based on page 5 (of 398) of the IRB correspondence file.

Subject Recruitment

Two recruitment firms, J. Reckner Associates, Inc. in Wisconsin and Herron Associates, Inc. in Florida were contracted to recruit potential candidates for these studies.

J. Reckner Associates compiled and maintained a list of subjects for Wisconsin and Herron

Associates did the same for Florida. A total of 6950

- 6953 potential candidates served as

the ini tial pool. Using the approved script for the initial phone call, the recruitmen t firms

screened 392

- 395 subjects. Using the approved inclusion/exclusion criteria, and taking into account subjects’ availability and interest, the recruitment firms identified and

scheduled 1 70

- 173 subjects for S.C. Johnson to contact and further screen . There were three additional subjects recruited between 9/10/15 and 9/15/15, so the studies with test days of 9/15/15 and later had a slightly larger pool than those studies whose latest test dates

were 9/10/15 and before. Using the approved follow

- up screening script, the interested subjects who met the inclusion/ exclusion criteria and were available for both the training

and test dates were enrolled for studies. T his approach was used for all five studies shared with the Human Studies Review Board (HSRB).

For the Mark

- 5 study, 44 subjects were enrolled . As described on page 13 of the study, the pool of enrolled subjects generally represented the demographics of U.S. repellent users. S.C. Johnson indicated that they made every effort to recruit and schedule subjects to fit the targeted demographics per the protocol. Not all targets were met due to: 1) availability of subjects for the training and test dates; and 2) subjects withdrawing on the training and test day; and 3) subjects not showing up to their scheduled training and/or test dates. A broad range of demographics was still represented in the study looking at the combined demographic data for the human subj ects participating in the Florida and Wisconsin testing. Table 5 in the completed study provides the demographics. Table 6, included in Attachment 2 to this memo, summarizes figures on subject recruitment, while Table 7 (also in Attachment 2) summarizes su bject participation.

Subject Inclusion/Exclusion Criteria

Consistent with the approved protocol, t he following inclusion/exclusion criteria were used for subject selection:

1. Subjects were within the ages of 18

- 55 and provided proof of age by a driver's license, passport, or other valid identification.

2. Subjects could read and speak English fluently. A percentage of bilingual subjects (English plus another language) were recruited for each study.Page 5 of 22 3. Subjects were not employees of S

. C

. Johnson or immediate family members of SC Johnson employees.

4. Subjects had a reliable form of transportation to get to and from the test and training

locations.

5. Subjects were willing to be exposed to and potentially bitten by mosquitoes and

were not known to be hypersensitive to mosquito bites.

6. Subjects felt they were healthy enough and did not have any health conditions that would make them unable to sit in a chair for long periods, with breaks for limb stretching and movement at reasonable interva ls, able to stand continuously for five minutes and be outdoors for several hours where high temperatures, high humidity and sweating were possible

7. Subjects were willing to participate in testing outdoors where high temperatures, high humidity and sweatin g were possible.

8. Subjects did not have a known sensitivity or allergy to mosquito bites, Elastikon (or equivalent) tape, latex, insect repellents, or skin care products.

9. Subjects were free of skin disease, skin problems, such as eczema, psoriasis, or

ato pic dermatitis.

10. Subject were willing to refrain from using alcohol 12 hours before the test, and refrain from nicotine, and fragrance products (e.g., soap, perfume, cologne, hair spray, lotion, etc.) during the test.

11. Female Subjects were not pregnant or breast

- feeding.

12. Mosquitoes were attracted to subjects' untreated skin

.

13. Subjects were users of insect repellent products.

Consent Process

Each potential subject who expressed interest in participating in the study and met
the inclusion/exclusion criteria met with the Study Director or Principle Investigator at the scheduled training session. At this session, the subjects were provided with copies of the informed consent document ( ICD ) and asked to read the entire document. In cases where

S.C. Joh nson had an email address for eligible subjects, S.C. Johnson emailed the consent form to the subjects in advance of the training session . During the training, a fter the subjects completed reading the consent form, the Study Director or Investigator asked the subjects if they had any questions regarding the information in the consent form, the study, and their role in the study. S.C. Johnson answered a ny questions . I f a subject still wishedPage 6 of 22 to enroll in the study, he or she was asked to sign their copy of the ICD and the Study Director or Sub Investigator witnessed the signature. S.C. Johnson gave e ach subject a copy of his or her signed ICD.

Training

The subjects were trained in the skill of aspirating blood

- seeking mosquitoes prior to participating in the study. In Wisconsin, training took place in the lab at the S

. C

. Johnson

and Son Inc. Entomol ogy Research Center in Racine, Wisconsin

. In Florida, training

occurred i n the field at Collier Seminole State Park in Naples, Florida.

In Wisconsin, lab

- reare d female Aedes aegypti (yellow fever mosquitoes) were used. These mosquitoes were from colonies which have been fed only on animal hosts, never on humans, for many years. These mosquitoes were free of any disease

- causing organisms which can afflict humans. Ten mosquitoes were released in a 2' x 2' x 2' screened cage with two entry ports. The study staffer demonstrated how to aspirate mosquitoes from their own bare forearm by inserting both arms into the cage, a battery

powered aspirator held in one hand (th is forearm was protected by a long sleeve). When a mosquito landed on the staffer's bare forearm, it was observed fo r the distinctive posture it

ado pts when preparing to bite. The mosquito was aspirated before it could bite. The same procedure was followed with additional mosquitos.

After the subjects watched at least eight mosquitoes captured in this way by the study staffer, they were asked to try it themselves in the same manner. The study staffer observed these attempts closely and provided guidance as needed. The subjects were given additional mosquitoes to aspirate until the staffer felt that they were sufficiently proficient to participate in the field test. All mosquitoes from this training session were killed by exposure to compressed carbon dioxi de and disposed in the trash.

In Florida, an appropriate laboratory site for tra ining was not available. Instead, the subjects underwent training in the field at Collier Seminole State Park in Naples, Florida. This possibility and approach was described in section 8.2 of the approved protocol. The Study Director located an outdoor area where the mosquito landing rate was adequate to supply wild mosquitoes for practice, but not so heavy that trainee subjects were overwhelmed with mosquitoes while learning to aspirate. Both the staff members and test subjects wore bug suits to protect the entire body from mosquitoes and gloves over the hands. A study staffer demonstrated how to aspirate mosquitoes from their suit protected forearm with the battery powered a spirator. When a mosquito landed on the staffer's forearm, it was observed fo r the distinctive posture it ado pts when preparing to bite and the mosquito was aspirated. The same procedure was followed with additional mosquito e s. After the subjects watched a t least eight mosquitoes captured in this way by the study staffer, they were asked to try it t hemselves in the same manner. The study staffer observed these attempts closely and provided guidance as needed. The subjects practiced aspiration

until the staf fer felt that they were sufficiently proficient to participate in the field test. No skin was exposed to biting mosquitoes during the training.Page 7 of 22 Exclusion of Pregnant Women

The pregnancy test was performed by the potential subject alone in a private

bat hroom. The results were verified by the subject only. After completion of the pregnancy test, a female member of the study staff asked in a private setting if the potential subject is still interested in participating in the study. If they were no longer i nterested, they did not need to explain why. If the test subject was interested in participating, the results were verified by a female of the study staff in a private manner. The results were kept confidential, were not recorded, and were not disclosed to anyone. The female staff member only notified the Study Director which females were and were not participating in the study. S.C. Johnson confirmed for EPA that pregnancy testing for each study was

conducted on the training day in all cases. If the test day occurred more than 48 hours after the training day, the pregnancy test was repeated on the morning of the test day . This was

consistent with section 2.3.12 of the approved protocol. No pregnant or nursing female subjects participated in the study.

Mi tigation of Hazards

As described in the approved protocol and completed study, there were five types of hazards associated with the study, including : adverse reaction to the test substances; exposure to biting mosquitoes; exposure to mosquito

- vectored dis eases; general risks of being in the field; and unanticipated loss of confidentiality. Pages 1 7

– 19 of the completed study describes the precautions taken to mitigate those hazards. Some examples of these precautions are included in this memo and are co nsistent with the protocol approved in advance of the study.

No subjects with known allergies to mosquito bites were allowed to participate as a test subject. Subjects received specific training on how to remove mosquitoes from their skin before they were bit ten . In addition, test subjects only exposed one forearm for mosquitoes to land. For untreated control subjects who were at greater risk of being bitten, when they received five lands within the 5

- minute exposure (the minimum necessary to

ensure a dequate mosquito landing rate), they covered their exposed limbs by rolling down

their sleeve.

In the U

. S

. , mosquitoes can transmit various disease

- causing organisms to humans, notably the West Nile virus. All subjects were instructed as to what symptoms of these diseases may look like, so they could seek informed medical care in the very unlikely event they contracted any of these diseases and became symptomatic. To reduce the risk of contracting any mosquito

- borne diseases, the study was conducted in a reas where the presence of mosquito

- borne disease had not been detected by county or state health staff or mosquito abatement district staff within one month prior to the test date. The Study Director continually monitored for emerging reports of mosquito borne diseases in the area of the test locations prior to the test date and within two weeks following the test date. The Study Director consulted the USGS, CDC and State Health Department websites to monitor reported mosquito borne disease in areas for th e county where the test location resided. Study staff provided food and non

- alcoholic beverages on site, and encouragedPage 8 of 22 subjects to drink regularly to keep hydrated. A tent enclosure was provided to keep subjects away from mosquitoes between test exposure periods and shade was also provided to protect them from direct sun. In addition, ample seating was provided to subjects participating in testing. (For the information of the HSRB, the protocol did not explicitly state that seating would be provided to subjects. However, the seating was a positive difference which provided some comfort to subjects and it was implied in protocol section

10.5.2.6 which st ates that “ test subjects will be instructed and reminded on how to properly

sit and stand during study to not lean on or rest against the treated skin

. ” Furthermore, the approved inclusion/exclusion criteria referenced, in part, that a subject should be a ble to “sit in a chair for long periods, with breaks for limb stretching and movement at reasonable intervals, able to stand continuously for five minutes...”. In the future, EPA wil l suggest that the provision of seating be included , as appropriate, in t he section on mitigating risk ; this would be included only if discomfort from testing was likely to occur and the seating alleviated it. In this case, S.C. Johnson took the initiative to provide ample seating in each of their mosquito repellent studies .)

Staff were cognizant of the types of wildlife they may find in the areas where testing was conducted, and moved subjects away from areas where they found potentially harmful organisms, such as fire ants and wasps. Staff also encouraged subjects to perform frequent tick checks to remove any acquired ticks before they had opportunity to bite. No reports of any tick activity occurred during the test. Subjects were told that if anyone experienced any skin reaction, experienced an injury, or simply felt unwell , he or she was to inform study staff right away. Such subjects would immediately be given appropriate care, and could withdraw from testing. As of December 10 , 2015, S.C. Johnson had not received any reports of adverse reactions after the test.

Subjects were advised on several occasions that they could withdraw from the study for any reason, without penalty. However, if they chose to withdraw early due to a non

health related reason, they would only be paid for the hours in which they have participated. No subjects withdrew from this study.

Confidentiality

The identity of each subject was protected in the following ways consistent with the approved protocol:

• Each sub ject was assigned a code number;

• Only subjects' code numbers appear on data sheets and i n the reports;

• Study records were maintained in locked cabinets and electronic files kept on a

pas sword

- protected computer server; and

• No one outside of the study sponsor, study staff, the recruitment firm, the IRB, or certain governmental agencies (such as U

. S

. EPA) will have access to subjects' personal information.

CompensationPage 9 of 22 Subjects were paid $60 for participating in an approximately 3

- 4 hour training session conducted prior to the field testing. Test subjects that chose to withdraw or were

asked to withdraw from the training session were still paid $60 for attending all or part of the training session. For each field test day, subjects were paid $15 per hour for the test day. If a test day exceeded 8 hours, subjects were paid $18 for each addition al hour beyond the first 8 hours, rounded up to the nearest hour. Test subjects who chose to withdraw or were asked to withdraw on the test day were still paid for the hours they participated. All subjects were paid for the hours in which they participated , from the time they arrived on site until the time they departed. The alternates, if they were not needed on the test day to replace an absent or withdrawn test subject, were paid $50.

Protocol Amendments

There was one amendment to the protocol that ch anged the study director given that the original director went on a 10 week sabbatical. The amendment was approved by the SAIRB prior to implementation.

Protocol Deviations

Appendix B to the study document s four protocol deviations on pages 11 1

- 11 4 (of

150 )

. These deviations did not raise ethical concerns or result in ethical deficiencies.

The deviations listed in the report did not negatively affect participant s’ rights or their health or safety

. S.C. Johnson adhered to the IRB instructions and protocol regarding documentation of deviations. As stated in section 13 of the protocol, “The amendments, deviations, as well as any adverse events will be documented in the Study Director's final report. Do cumentation will include a description of the change, the reason for the change and the effect of the change on the conduct and outcome of the study.”

Regulatory and Statutory Standards

The following provisions of 40 CFR 26 Subpart Q, as amended

, defin e the applicable ethical standards, which read in pertinent part:

§26.1703: Excep t as provided in §26.1706, EPA must not rely on data from any research subject to this subpart involving intentional exposure of any human subject who is a pregnant woman (and therefore her fetus), a nursing woman, or a child.

§26.1705: Except as provided in §26.1706, EPA must not rely on data from any research subject to this section unless EPA determines that the research was conducted in substantial compliance with all applicable provisions of subparts A through L of this part.

In addition, §12(a)(2)(P) of the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) applies. This passage reads:Page 10 of 22 In general, [i]t shall be unlawful for any person . . . to use any pesticide in tests on human beings unless such human beings (i) ar e fully informed of the nature and purposes of the test and of any physical and mental health consequences which are reasonably foreseeable therefrom, and (ii) freely volunteer to participate in the test.

Findings

Prior HSRB and EPA Review

Because thi s study was initiated after April 7, 2006, prior submission of the protocol and supporting materials to EPA was required by 40 CFR §26.1125. The requirements of 40 CFR §26.1125 for prior submission of the protocol to EPA and of §26.160 6 for HSRB review of the protocol were satisfied. The study protocol was approved by the SAIRB prior to submittal to EPA. The HSRB discussed the protocol at its April 22

- 23 , 2014 meeting, and concurred with EPA’s assessment that the protocol , if revised as suggested by the Ag ency and the HSRB , would meet the applicable requirements of 40 CFR part 26, subparts K and L.

Responsiveness to HSRB and EPA reviews

EPA’s and the HSRB’s ethics comments on t he protocol were addressed before the

research was conducted

. Please see Attachment 3 for details.

Prohibition of research involving inte ntional exposure of pregnant or nursing

women or of children

All enrolled subjects were at least 18 years old and there were no pregnant or nursing female subjects. The prohibition in 40 CFR §26.1703 of research involving intentional exposure of pregnant or nursing women or of children under age 18 was

satisfied.

Substantial compliance with 40 CFR 26 subparts A through L

40 CFR § 26.1705 requires that EPA not rely on data from any research subject to

this section unless EPA determines that the research was conducted in substantial compliance with all applicable provisions of subparts A thr ough L of this part. Within this range, only subparts K and L are directly app licable to the conduct of third

- party research

such as this

. The study document s substantial compliance with subparts K and L.

Compliance with 40 CFR 26 subpart M

As documented in Attachment 1 to this review, the central requirements of 40 CFR 26 subpart M, §26.1303 to document the ethical conduct of the research were satisfactorily

addressed.Page 11 of 22 Compliance with FIFRA §12(a)(2)(P)

The requirement of FIFRA §12(a)(2)(P) that human subjects of research be “fully informed of the nature and purpose s of the test and of any physical and mental health consequences reasonably foreseeable therefrom,” and “freely volunteer to participate in the test,” was met for this study.

EPA Conclusion

The study entitled, “ Field Testing of S.C. Johnson Personal Mosquito Repellent Products to Support their Use of the EPA Repellency Awareness Graphic” for test

substance MARK

- 5 d escribes research conducted in substantial compliance with the applicable requirements of 4 0 CFR 26 , subparts K and L. The conduct of the study met all applicable ethical standards for the protection of human subjects of research, and requirements for documentation of ethical conduct of the research were satisfied.

If this study is determined to be scientifically valid and relevant, there is no regulatory barrier to EPA reliance on it in actions under FIFRA or §408 of FFDCA

.

Attachment 1: §26.1303 Completeness C heck list

Attachment 2: Tables 6 and 7 from Completed Study

Attachment 3 : Responsiveness to EPA an d HSRB Ethics Comments on Draft P rotocolPage 12 of 22 

### Attachment 1
§ 26.1303 Checklist for Completeness of Reports of Human Research Submitted for EPA Review

Any person who submits to EPA data derived from human research covered by this subpart shall provide at the time of submission information concerning the ethical conduct of such research. To the extent available to the submitter and not previously prov ided to EPA, such information should include:

Requirement Y/N Comments/Page References(a) Copies of all of the records relevant to the research specified by §26.1115(a) to be prepared and maintained by an IRB § 1115(a)(1): Copies of

• all research proposals reviewed,

• scientific evaluations, if any, that accompany the proposals,

• approved sample consent documents,

• progress reports submitted by investigators, and reports of injuries to subjects. Y
n/a

Y
n/a The IRB

- approved protocol and consent form were previously reviewed and commented on by
the Human Studies Review Board (HSRB ).

§ 1115(a)(2): Minutes of IRB meetings which shall be in sufficient detail to show

• attendance at the meetings;

• actions taken by the IRB;

• the vote on these actions including the number of members voting for, against, and abstaining;

• the basis for requiring changes in or disapproving research;

• a written summary of the discussion of controverted issues and their

resolution. Y Minutes were previously provided
to EPA and HSRB members when the protocol was submitted for

review. Minutes for IRB meetings on 2/3/15 and 7/7/15 are provided

in Volume 2

- IRB Correspondence for Completed Research Submissions of Field Testing of S.C. Johnson Personal Mosquito Repellent Products to Support Their Use of the EPA Repellency Awareness Graphic, D. Hol las, Sept. 28, 2015, 398 pages.

§ 1115(a)(3): Records of continuing review (CR) activities. n/a According to the SAIRB, the CR will occur in February 2016.

§ 1115(a)(4): Copies of all correspondence between the IRB and the investigators. Y WIRB correspondence provided in a separate file to the HSRB.

Please see Volume 2

– IRB Correspondence for Completed
Research Submissions of Field Testing of S.C. Johnson (SCJ) Personal Mosquito Repellent Products to Support Their Use of the EPA Repellency Awaren ess Graphic, D. Hollas, Sept. 28, 2015, 398 pages. Note that this Volume 2 was submitted along with the completed study for Test
Substance MARK

- 2, GLP study 864E1. However, Volume 2 applies to all SCJ studies which followed protocol no. 90017040.

Relevant pages in Volume 2: 5,

102

- 105, 117

- 121, 124

- 137, 161

- 180, 373

- 398. § 1115(a)(5):

• A list of IRB members identified by name; earned degrees; representative capacity; indications of experience such as board certifications, licenses, etc., sufficient to des cribe each member’s chief anticipated contributions to IRB deliberations;

• any employment or other relationship between each member and the

institution Y

Y Previously provided to HSRB members with the protocol. Updated information was included

in a separate file provided to
HSRB members with the completed study. See Volume 2 (with title identified in cell above). Please see pages 373

- 374. § 1115(a)(6): Written procedures for the IRB in the same detail as described in § 26.1108(a) and § 26.1108(b). Y Previously provided to EPA.

§ 1115(a)(7): Statements of significant new findings provided to subjects, as required by § 26.1116(b)(5). n/aPage 13 of 22 Requirement Y/N Comments/Page References(b) Copies of all of the records relevant to the information identified in§26.1125(a)-(f)§1125(a)Adiscussion of: (1) The potential risks to human subjects; Y Discussed in consent form and section 2.8 of revised protocol.

Please note that the revised protocol is attached to and submitted with each completed study.

(2) The measures proposed to minimize risks to the human subjects; Y Discussed in consent form and section 2.8 of revised protocol. (3): The nature and magnitude of all expected benefits of such research, and to whom they would accrue; Y Discussed in consent form and
section 2.9 of revised protocol. (4) Alternative means of obtaining information comparable to what would be collected through the proposed research; and Y Discussed in consent form and section 2.1 of revised protocol
discusses rationale for human subjects.

(5) The balance of risks and benefits of the proposed research. Y Discussed in revised protocol including section 2.9. § 1125(b): All information for subjects and written informed consent agreements as originally provided to the IRB, and as approved by the IRB. Y Provided in separate file to EPA
and HSRB. § 1125(c): Information about how subjects will be recruited, including any advertisements proposed to be used. Y Section 2 of revised protocol.

§ 1125(d): A description of the circumstances and methods proposed for presenting information to potential human subjects for the purpose of obtaining
their informed consent. Y Revised consent form, and section 2.4 of revised protocol.

§ 1125(e): All correspondence between the IRB and the investigators or

spons ors. Y Separate file provided to HSRB with requests sent to IRB and

responses. § 1125(f): Official notification to the sponsor or investigator, in accordance with the requirements of this subpart, that research involving human subjects has

been reviewed and approved by an IRB. Y See Volume 2 provided to HSRB.

(c) Copies of sample records used to document informed consent as specified by §26.1117, but not identifying any subjects of the research Y Revised consent form approved by IRB was provided to HSRB. (d) If any of the information listed in paragraphs (a) through (c) of this section is not provided, the person shall describe the efforts made to obtain the information. n/aPage 14 of 22 

### Attachment 2

– Table 6

– Su bject Recruitment Summary (as of 9/18/15)

Number of subjects initially contacted by recruitment firms 695 3 Number of subjects interviewed by recruitment firms 39 5 Number of subjects screened by SCJ study staff 17 3



### Table 7 Summary of Test Participation in GLP Study 867 E1
At EPA’s request, S.C. Johnson provided an updated Table 7 including the state

- specific information and any corrections to total

fi gures. New information is provided in red type.

GLP 867E1

- 4822

- 395 Wisconsin Florida Total

Number of Subjects Enrolled 24 20 44 *( Note: SC Johnson corrected the original figure of 45.)

Number of No

- Shows to training and/or testing No

- shows for training: 1

No

- shows for testing: 2 No

- shows for training: 7

No

- shows for testing: 0 10

** ( Note: S.C. Johnson corrected the original figure of 8. It should be 10; 8

no

- shows for training, 2 no

- shows for testing)

Number Assigned as Test Subjects 12 12 24

Number Assigned as Alternates or Extras 4 alternates (2 were used)

7 extras 1 alternate

0 extras 12 ***( Note: S.C. Johnson corrected original figure of 5; it should be 12)

Number of Test Subjects Withdrawn Voluntarily 0 0 0

Number of Test Subjects Withdrawn Involuntarily 0 0 0

Number of Test Subjects Completed Research 12 12 24

In Wisconsin: 12 test subjects (10 treated test subjects and 2
controls) and 4 alternates were randomly selec ted as described
in the report out of the pool of

23 trained participants

. In Florida: Only 13 trained
participants were available on
this test day . 12 test subjects (10 treated test subjects and 2
controls) and 1 alternate were
selected as described in the

report out of the pool of 13 trained participants

.Page 15 of 22 *typo

**no

- shows for testing were not previously included in the total

***7 extras were not previously included in the total



### Note s for HSRB:

Table 6

The numbers listed in Table 6 in each of the ethics and science review memos are accurate for each of the studies. S.C. Johnson highlighted for EPA that t here were 3 additional test subjects recruited between 9/10 and 9/15, so the studies with test days of 9/15 and later had a slightly larger pool than those studies whose test dates were 9/10 and before.



### Table 7

Table 7 includes a reference to “number assigned as alternates or extra s.”

At EPA’s request, S.C. Johnson provided the following explanation of “extras.”

“’Extras’ was the term we used for individuals who attended training but were not randomly selected as a treated subject, untreated control, or alternate. If we had more than 16 people complete training, there would be extra individuals not needed for the test. The extras would have signed the consent form and would have been paid for their attendance at the training session, the same as all other participants attending training. Extras were not requested to show up on test day. ”Page 16 of 22 

### Attachment 3

– S.C. Johnson Mosquito Repellent Completed Studies

-

Responsiveness to EPA and HSRB Ethics Comments on Draft Protocol

Comment from EPA and /or HSRB Action taken by S tudy Sponsor

1. Please revise the benefits section of the

Informed Consent Form as follows: “You will not personally benefit from this study

, other than the financial compensation .” The proposed payment to subjects is considered compensation for lost time and inconvenience, not a benefit of participating in the research. This study provides no direct benefits to subjects. The study sponsor addressed thi s comment and deleted the requested language on page 9 of the

IRB

- approved final consent form (dated July 10, 2015).

(Volume 2 to the study for test substance

MARK

- 2 provides the IRB correspondence that impacts all of the completed studies based

on the same protocol. The final consent form can be found in Volume 2, on pages 84

- 94 of

398. Volume 2 is entitled IRB Correspondence for Completed Research Submissions of Field Testing of S.C. Johnson (SCJ) Personal Mosquito Repellent Products to Support Their Use of the EPA Repellency Awareness Graphic, D. Hollas, Sept. 28, 2015, 398 pages. )

2. Johnson should inquire with the recruiting firm about the demographics of the volunteer pool from which subjects will be recruited, and provide additional details in the protocol to support the statement that the pool of subjects will be demographicall y and ethnically representative of the population in the area where the field testing will be conducted. The pool of subjects should also be representative of the overall population of concern, which is repellent users in the United States. The study spon sor addressed this comment in the expanded section 2.2.3 of the protocol

which includes additional details.

3. The protocol excludes Johnson employees from becoming subjects. Please amend the protocol and consent form to also exclude immediate family members of Johnson employees. As requested, the study sponsor excluded family members on page 3 of the final IRB

approved consent form (dated July 10, 2015).

4. Johnson should consider whether additional stopping rules should be added to the protocol. Examples of conditions which The study sponsor expanded the language in protocol section 11.2.6 to address this

comment. T he sponsor added the followingPage 17 of 22 may be appropriate to trigger a stop to the research (either for an individual participant or for the whole study) include: mosquito landing rate falls below threshold needed to challenge test material, wind speeds exceed
a certain level, s ubject asks to withdraw, subject exhibits hypersensitivity to insect bites, subject exhibits sensitivity to the test material, medical management is invoked. The first two examples would apply to the entire study; the other examples would apply to an individual subject. languag e: “If the test subjects asks to withdraw, if any adverse reactions or sensitivity such as redness, edema, itching, or pain to the test substance are observed or reported, subjects exhibit hypersensitivity to insect bites and/or any medical management is

n eeded, the test subject will be removed from the test immediately.”

5. The protocol and consent form must explain how compensation will be handled if a potential subject participates in the consent meeting, the training meeting , and/or the pregnancy testi ng, but then ultimately

decide s not to participate in the research. The study sponsor addressed this comment. In section 2.2.6 of the protocol, the sponsor added the following language: “Test subjects that

choose to withdraw or asked to withdraw from

the training session will still be paid $60.00 for attending all or part of the training session.” In section 2.2.7 of the protocol, the sponsor added, “Test subjects that choose to withdraw or are asked to withdraw from the study on the test day will still b e paid for the hours which they participated on that test day (however, this will not affect payment for any previous test days in which the subject may have already participated).” The same topics were addressed in the compensation section in the

final c onsent form. Finally, these topics were

also addressed in sections 12.2.5 and 12.2.6 of the final study.

6. The protocol and consent form should be

revised to include details about whether subjects will be transported by the

researchers to and from the t esting site

. If the testing site is remote, and if Johnson

intends to transport the subjects to the testing site, then Johnson should make arrangements to transport any subjects who

withdraw back to the starting location within a short period of time after that subject indicates his or her desire to

withdraw . If Johnson cannot make such arrangements, then a subject who withdraws should be paid for all of the time spent at the study site, even if he or she has chosen The final consent form was updated to state:

“You must have a reliable form of transportation to get to and from the test and training locations. You are responsible for your own transportation to the [and] from the training and test site locations.”

Section 2.3.4 of the final protocol was expanded to state, “Subjects are responsible for their own transportation to and from the training and test si te locations.”Page 18 of 22 to withdraw early. Not compensating a

sub ject for this type of time and

inconvenience could unduly influence him

or her to continue participating.

7. The protocol provides that the entire

consent document will be read aloud to potential subjects during the consent meeting. Given that the ability to read English is a requirement to participate, Johnson should offer subjects the option of reading the consent form themselves. If Johnson wishes to confirm understanding of
the consent form, Johnson should draft several questions to be asked of each potential subject prior to them signing the consent form, and those questions should b e included in the revised materials that are reviewed by SAIRB before the study is

initiated. The study sponsor revised section 2.4.1 of the protocol to include the new language underlined below: “Prior to participating in any aspect of the test, each potential subject who has expressed interest in participating in the study and has met the inclusi on/exclusion criteria will meet with the Study Director or Principle Investigator at the scheduled training

session. At this session, the subjects will be provided with copies of the Informed Consent

Document and will then be asked to read the

entire docu ment .”

In addition to the revision to section 2.4.1 noted above, section 2.4.2 was also revised to

state ”After the potential subjects have completed reading the consent, The Study Director or Principle Investigator will ask the subjects if they have a ny questions regarding the information in the consent form, the study and their role in the study. Any questions will be

answered.”

In addition, the screening document was revised to make it clear that the subjects could request a copy of the consent doc ument in

advance for their review. S.C. Johnson confirmed that, s ince most of the test subjects asked for a copy of the consent document at this poin t, their practice was to send the consent form via email to all eligible test subjects.

Given the changes above, it was determined that additional questions to confirm understanding of the informed consent document were not necessary; all test subjects could read and speak English, all test subjects were given ample time and opportunity to read

the consent fo rm and ask questions about it, and study staff asked each test subject if theyPage 19 of 22 had any questions about the consent document. Any questions were answered.

8. The protocol should discuss whether the number of repeat tests per person should be

limited. The re should be some plan to

follow

- up with subjects after their participation in the study has ended to check for any delayed consequences of study participation. This could consist of a phone

call to check on health status. The protocol did not limit the number of repeat

tests per person

. S.C. Johnson provided the following explanations:

a. All products which are subject to this protocol are registered by EPA and have been previously evaluated for safety.

b. There were and are no anticipated hazards from rep eated use.

c. Since the protocol dictated that a

minimum of tw o full calendar days

would occur between treatments, it was not expected that residual active ingredient would be present in a later study.

d. T he protocol called for exposure to

be controlled by expo sing the test subjects to no more than the typical

use rate.

e. Exposure was further minimized by instructing each participant to

wash their treated limb at the conclusion of the study.

f. Test subjects were monitored during the study, so if an adverse

reactio n was noted, they could be removed from the study and avoid subsequent exposure.

As of December 10 , 2015, S.C. Johnson had not received any reports of adverse reactions

after the test.

The study sponsor expanded protocol section 11.2.4 to state, “The Stu dy Director and recruitment firm will keep on file the phone numbers and addresses for each study participant as a means to contact them if needed.” This statement follows the pre

existing language that, “Subjects will be informed both verbally and in wri ting of any significant new findings, such as detection ofPage 20 of 22 mosquito borne disease in the area or product contamination, discovered during the course of the testing which may influence their continued participation.”

Section 11.2.8 was expanded to state, “Study staff will monitor and contact test participants if any mosquito borne disease cases are reported in the test area within two weeks following the test date.”

Language was already included in protocol

section 11.2.9 and in the consent form providi ng a 24 hour contact number that test subjects could use for any research

- related

issues or concerns.

Follow

- up was deemed necessary only if S.C. Johnson came into possession of new information about which the test subjects should be notified consistent with the protocol.

On the topic of following up with subjects

, prior to S.C. Johnson finalizing the prot ocol, OPP told S.C. Johnson that the expanded

information described above was sufficient.

9. The protocol team should provide a process to contact subjects in the unlikely event that new information is developed or discovered as a result of the study, fo r example, if mosquitoes were discovered with vector

borne disease or if a contaminated product

was identified. The study sponsor expanded protocol section 11.2.4 to state, “The Study Director and recruitment firm will keep on file the phone

numbers and addresses for each study participant as a means to contact them if needed.” This statement follows the pre

existing language that, “Subjects will be informed both verbally and in writing of any significant new findings, such as detection of mosquito born e disease in the area or product contamination, discovered during the course of the testing which may influence their continued participation.”

Section 11.2.8 was expanded to state, “Study staff will monitor and contact test participants if any mosquito borne disease cases are reported in the test area within two weeks following the test date.”Page 21 of 22 Protocol section 2.8.2.5 was also expanded to further reduce the risk of contracting any mosquito

- borne disease and include the following language: “The study director will consult USGS, CDC and State health department websites that provide data on occurrences of mosquito borne disease by state and by county in each state. The study director will contact local State Health Departments to inquire about cases of mosquito borne disease

if information cannot be found on the website and will contact Mosquito Control Districts to inquire about cases of mosquito borne disease if available in the county of the test location. In the event that testing occurs outside of the U.S., similar resources for determining the presence of mosquito borne disease, such as the Queensland health Website, will be consulted prior to any international testing.”

10. The protocol team should provide a justification, in the protocol or IRB documents, for excluding non

- English speakers, especially at the Florida site where Spanish

- speakers are a significant proportion of the population; or if no justification for exclusion is provided, the protocol should be amended to include Spanish speake rs. In order to assess the representativeness of the study population, the protocol team should provide to EPA general information on population demographics of subject pool at each site,

and some information about recruitment strategies. This is particula rly important if

alternate sites located outside of the U.S. are

used. The revised protocol addressed this comment.

The original section 2.2.3 of the protocol did not provide details on the demographic targets. The revised section 2.2.3 provides details on the demographic targets.

With regard to the requested justification language, the protocol was revised to state: “This pool will generally represent the demographics of US repellent users. Current repellent product labels are in English, so to target users familiar with and that understand the product labels, we will be recruiting English speaking subjects. This r esearch does not offer benefits to the subjects, so limiting recruitment to English speakers does not result in equity

- of

- access issues. In addition, the language that someone speaks does not directly affect attractiveness to mosquitos. SCJ will

target r ecruiting a minimum of 10% bilingual (English and another language) to help not restrict recruitment to only English speakers.” After this language, the revised protocol

includes 2015 Neilson data related to U.S. repellent users.Page 22 of 22 11. The Board discussed two additional aspects of the study that could benefit from clarification. The Board expressed concern regarding the statement in the consent document that care and compensation for injury would be handled similar to a workers compensation claim. It was no t clear if this was an appropriate mechanism for care and compensation in a research study. The consent form states “This study

is considered confidential.” The Board questioned whether this is intended to refer to data collected on individual subjects or whether the details of the study should not

be disclosed or discussed with others. In the consent form, the study sponsor deleted the worker compensation claim language that

concerned the HSRB and revised the applicable section to read as follows: “Compens ation for Injury: In the unlikely event that you are injured as a result of your participation in this study, medical care will be made immediately available. The sponsor will reimburse you for the costs of this care. If you believe you may have suffere d any physical or mental side effects as a result of your participation, please contact the Study Investigator using the phone number on page 1

of this document. All adverse effects will be

followed until resolution is reached. There are no plans to prov ide other compensation beyond

that which is listed in this informed consent document. You will not lose any of your legal rights or release the Sponsor, the study doctor, the study staff, or study site from liability for

mistakes or intentional misconduct by signing

this consent document.”

Regarding confidentiality, the study sponsor clarified the consent form in response to the comment. The sentence in question stated that, “This study is considered confidential.” After this sentence, the study sponsor clarified that “The details of the study should not be

discussed or disclosed with others not involved with the study. All data collected on individual subjects is also confidential.” (This is included on page 93 of 398 in Volume 2.)